KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Ratio (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Equity Ratio for 7 consecutive years, with 0.5 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 12.76% to 0.5 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.5 through Dec 2025, down 12.76% year-over-year, with the annual reading at 0.5 for FY2025, 12.76% down from the prior year.
  • Equity Ratio hit 0.5 in Q4 2025 for Royalty Pharma, roughly flat from 0.5 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.63 in Q2 2021 to a low of 0.5 in Q4 2025.
  • Historically, Equity Ratio has averaged 0.57 across 5 years, with a median of 0.58 in 2022.
  • Biggest five-year swings in Equity Ratio: increased 8.66% in 2023 and later dropped 12.76% in 2025.
  • Year by year, Equity Ratio stood at 0.59 in 2021, then decreased by 3.17% to 0.57 in 2022, then grew by 8.66% to 0.62 in 2023, then decreased by 7.8% to 0.57 in 2024, then decreased by 12.76% to 0.5 in 2025.
  • Business Quant data shows Equity Ratio for RPRX at 0.5 in Q4 2025, 0.5 in Q3 2025, and 0.52 in Q2 2025.